
The fourth annual Raise Your Hand campaign launched this week, and it’s already creating a social media buzz. This campaign, sponsored by Lundbeck, raises awareness and support for rare disease research. It also gives a spark of hope to patients previously left on the sidelines in the quest for a treatment. read more >
Reprinted with permission from FDA Matters: By Steven Grossman
The Orphan Drug Act (ODA) turned 30 this month, demonstrating that good laws really can have an enduring impact. Amidst the celebrations, a reporter asked me a provocative question: Can we afford more orphan drugs costing hundreds of thousands of dollars per year? FDA Matters answered “yes”. read more >
An article in the January issue of Therapeutic Innovation and Regulatory Science (formerly the Drug Information Journal) offers continuing insights into how the pharmaceutical and biotechnology industries and their regulators need to be thinking about drug development for the future … and these insights are particularly appropriate when it comes to the rare disease space. read more >
Whole genome sequencing (WGS) is the genetic test that determines the order of all 3 billion letters in a person’s DNA, and is a technology that has become well known to the rare disease community. It can reveal not only the genes responsible for production of an abnormal protein associated with a disease, but also the presence of other abnormal genes or variations in gene structure and regulation. Success stories describing the use of this technology to help some individuals with rare diseases overcome the “odyssey of diagnosis” have been widely reported (links below) with understandably great enthusiasm, and this technology holds enormous promise for continuing to uncover the underlying causes of rare diseases. read more >
RareDisease Dialog is the official blog for the National Organization for Rare Disorders (NORD). NORD’s staff and friends will share information of interest to the entire rare disease community.
Featured Partnerships |
Translate This page: |
|
SUBSCRIBE TO OUR E-NEWS |



